Approaching untargetable tumor-associated antigens with antibodies.
about
Trial Watch: Peptide-based anticancer vaccines.Trial watch: Naked and vectored DNA-based anticancer vaccinesBuilding better monoclonal antibody-based therapeutics.PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo
P2860
Approaching untargetable tumor-associated antigens with antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Approaching untargetable tumor-associated antigens with antibodies.
@en
Approaching untargetable tumor-associated antigens with antibodies.
@nl
type
label
Approaching untargetable tumor-associated antigens with antibodies.
@en
Approaching untargetable tumor-associated antigens with antibodies.
@nl
prefLabel
Approaching untargetable tumor-associated antigens with antibodies.
@en
Approaching untargetable tumor-associated antigens with antibodies.
@nl
P2093
P2860
P356
P1433
P1476
Approaching untargetable tumor-associated antigens with antibodies.
@en
P2093
David A Scheinberg
P2860
P304
P356
10.4161/ONCI.24678
P577
2013-04-30T00:00:00Z